Literature DB >> 2358784

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.

J Han1, P Thompson, B Beutler.   

Abstract

The induction of cachectin/tumor necrosis factor (TNF) synthesis by bacterial endotoxins is a process that entails activation at several levels. Cachectin/TNF gene transcription is accelerated, leading to rapid accumulation of mRNA within the macrophage cytosol. In addition, translational derepression occurs, leading to far more efficient message utilization. Through the use of posttranscriptional reporter constructs, we now demonstrate that certain agents capable of inhibiting cachectin/TNF biosynthesis operate through different mechanisms. In RAW 264.7 macrophages, pentoxifylline blocks cachectin/TNF mRNA accumulation but has no effect upon the efficiency of reporter mRNA translation. Dexamethasone, on the other hand, has only a modest effect on cachectin/TNF mRNA accumulation, but strongly impedes translational derepression. Combined application of dexamethasone and pentoxifylline to macrophages causes a greater suppression of cachectin/TNF biosynthesis that can be achieved by either agent alone. These findings suggest that the signaling pathway activated by endotoxin is branched, and that selective inhibition of different parts of the pathway may be achieved through the use of distinct agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2358784      PMCID: PMC2188134          DOI: 10.1084/jem.172.1.391

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline.

Authors:  R M Strieter; D G Remick; P A Ward; R N Spengler; J P Lynch; J Larrick; S L Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

2.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

3.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

4.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

5.  Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein.

Authors:  K Cseh; B Beutler
Journal:  J Biol Chem       Date:  1989-09-25       Impact factor: 5.157

6.  Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells.

Authors:  M Kawakami; P H Pekala; M D Lane; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

7.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog.

Authors:  K J Tracey; S F Lowry; T J Fahey; J D Albert; Y Fong; D Hesse; B Beutler; K R Manogue; S Calvano; H Wei
Journal:  Surg Gynecol Obstet       Date:  1987-05
  7 in total
  108 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  Inhibition of human interleukin-12 production by pentoxifylline.

Authors:  D R Moller; M Wysocka; B M Greenlee; X Ma; L Wahl; G Trinchieri; C L Karp
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

4.  Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes.

Authors:  A M van Furth; E M Verhard-Seijmonsbergen; R van Furth; J A Langermans
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 5.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

6.  Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells.

Authors:  Daeho Cho; Young-In Kim; Jae Seung Kang; Eunsil Hahm; Yoolhee Yang; Daejin Kim; Seonghan Kim; Yeong Seok Kim; Daeyoung Hur; Hyunjeong Park; Young Il Hwang; Tae-Sung Kim; Wang Jae Lee
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

Review 7.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

8.  Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK.

Authors:  J L Swantek; M H Cobb; T D Geppert
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 9.  The role of inflammation as a pathogenic factor in the development of renal disease in diabetes.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

10.  IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells.

Authors:  S M Thakurdas; Z Hasan; R Hussain
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.